Page last updated: 2024-10-23
aspirin and Apple Peel Small Bowel Syndrome
aspirin has been researched along with Apple Peel Small Bowel Syndrome in 1 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Previous studies of gastroschisis have suggested that risk is increased for maternal use of vasoactive over-the-counter medications, including specific analgesics and decongestants." | 1.31 | Maternal medication use and risks of gastroschisis and small intestinal atresia. ( Mitchell, AA; Sheehan, JE; Werler, MM, 2002) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Werler, MM | 1 |
| Sheehan, JE | 1 |
| Mitchell, AA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
Fetal Outcome 4 - Incidence of Fetal Loss
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
Fetal Outcome 5 - Incidence of Spontaneous Abortion
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
Fetal Outcome 6 - Incidence of All Stillbirth
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
Incidence of Hypertensive Disorders of Pregnancy
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
Incidence of Perinatal Mortality
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
Incidence of Preterm Birth
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
Incidence of Small for Gestational Age (SGA)
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
Maternal Outcome 1 - Incidence of Vaginal Bleeding
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
Maternal Outcome 2 - Incidence of Antepartum Hemorrhage
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
Maternal Outcome 3 - Incidence of Postpartum Hemorrhage
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
Maternal Outcome 4 - Incidence of Maternal Mortality
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
Maternal Outcome 5 - Incidence of Late Abortion
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Maternal Outcome 6 - Change in Maternal Hemoglobin
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Maternal Outcome 7 - Incidence of Preterm, Preeclampsia
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Other Studies
1 other study available for aspirin and Apple Peel Small Bowel Syndrome